CSF1R and neoplasm: As the presence of CSF1R+ macrophages correlates with poor survival in various tumor types (39), a variety of small molecules and monoclonal antibodies (mAbs) directed at CSF1R are in clinical development, which represents an attractive strategy in tumor therapy (40).